SGLT2抑制剂在各种原因所致慢性心力衰竭的研究进展

摘要/Abstract

摘要： 随着医学的不断发展,众多疾病的治疗有了突破性进展,但各种原因所致的慢性心力衰竭（心衰）仍对人类的健康发出巨大挑战,新的治疗靶点迫在眉睫。钠-葡萄糖协同转运蛋白-2（SGLT2）抑制剂作为近些年新兴起的降糖药物,各项研究结果表明其除具有良好的降糖效果外,还对糖尿病及非糖尿病患者的心、肾功能表现出良好的保护作用。但其对心脏本身是否直接受益,以及具体作用机制,目前尚未明确。本文就其可能的作用机制、目前临床研究结果、指南相关推荐情况进行总结,探讨其目前进展。

宋静鸽, 刘坤. SGLT2抑制剂在各种原因所致慢性心力衰竭的研究进展[J]. 心血管病防治知识, 2023, 13(34): 93-96.

参考文献 23

[1]	McDonagh TA, Metra M, Adamo M, et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.
[2]	Ponikowski P, Voors AA, Anker SD, et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].European Heart Journal,2016,37(27):2129-2200.
[3]	Kemp CD, Conte JV.The pathophysiology of heart failure[J].Cardiovascular Pathology,2012,21(5):365-371.
[4]	Wright EM.Glucose transport families SLC5 and SLC50[J].Molecular Aspects of Medicine,2013,34(2-3):183-196.
[5]	Lescano CH, Leonardi G, Torres PHP, et al.The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation[J].Biochemical Pharmacology,2020,182
[6]	Han L, Qu Q, Aydin D, et al.Structure and mechanism of the SGLT family of glucose transporters[J].Nature,2021,601(7892):274-279.
[7]	中国心力衰竭中心联盟专家委员会.心力衰竭SGLT2抑制剂临床应用的中国专家共识[J].临床心血管病杂志,2022,38(8):599-605.
[8]	Kondo H, Akoumianakis I, Badi I, et al.Effects of canagliflozin on human myocardial redox signalling: clinical implications[J].European Heart Journal,2021,42(48):4947-4960.
[9]	Li Y, Xu G.Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges[J].Pharmacological Research,2022,176
[10]	Díaz-Rodríguez E, Agra RM, Fernández áL, et al.Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability[J].Cardiovascular Research,2018,114(2):336-346.
[11]	廖梦阳,廖玉华,余淼,等.SGLT2抑制剂治疗心力衰竭潜在机制的新认识[J].临床心血管病杂志,2022,38(1):1-6.
[12]	Packer M.Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis[J].Circulation,2022,146(18):1383-1405.
[13]	Zinman B, Wanner C, Lachin JM, et al.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes[J].New England Journal of Medicine,2015,373(22):2117-2128.
[14]	Neal B, Perkovic V, Mahaffey KW, et al.Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes[J].New England Journal of Medicine,2017,377(7):644-657.
[15]	Wiviott SD, Raz I, Bonaca MP,et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J].New England Journal of Medicine,2019,380(4):347-357.
[16]	Cosentino F, Cannon CP, Cherney DZI, et al.Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease[J].Circulation,2020,142(23):2205-2215.
[17]	McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J].New England Journal of Medicine,2019,381(21):1995-2008.
[18]	Packer M, Anker SD, Butler J, et al.Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure[J].New England Journal of Medicine,2020,383(15):1413-1424.
[19]	Anker SD, Butler J, Filippatos G, et al.Empagliflozin in Heart Failure with a Preserved Ejection Fraction[J].New England Journal of Medicine,2021,385(16):1451-1461.
[20]	Bhatt DL, Szarek M, Steg PG, et al.Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure[J].New England Journal of Medicine,2021,384(2):117-128.
[21]	Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction[J].New England Journal of Medicine,2022,387(12):1089-1098.
[22]	ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023[J].Diabetes Care,2023,46(Supplement_1):S140-S157.
[23]	Heidenreich PA, Bozkurt B, Aguilar D, et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2022,145(18)

SGLT2抑制剂在各种原因所致慢性心力衰竭的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨振. 益气活血法对老年气虚血瘀型失代偿期慢性心力衰竭患者心功能及血清NT-proBNP、CysC的影响[J]. 心血管病防治知识, 2023, 13(9): 28-30.
[2]	上官黎明, 张海誉. 贝那普利片联合美托洛尔片对高血压合并心力衰竭患者心功能及血GMP-140、CT-1水平的影响[J]. 心血管病防治知识, 2023, 13(9): 31-33.
[3]	罗玉梅. 芪红汤联合芪参益气滴丸治疗冠心病慢性心力衰竭的疗效观察[J]. 心血管病防治知识, 2023, 13(8): 19-21.
[4]	上官昌瑾. 生脉苓桂救心汤在改善老年射血分数降低型心力衰竭中医证候中的应用[J]. 心血管病防治知识, 2023, 13(8): 26-29.
[5]	赖少云. 全面护理在ICU心力衰竭患者中的效果观察及有效率分析[J]. 心血管病防治知识, 2023, 13(8): 33-36.
[6]	庞建萍, 李少枝, 贺青军. 基于纽曼系统的多学科协作健康教育在慢性心力衰竭患者中的应用[J]. 心血管病防治知识, 2023, 13(8): 49-52.
[7]	刘晓艳. 沙库巴曲缬沙坦治疗扩张型心肌病并慢性心力衰竭患者的研究[J]. 心血管病防治知识, 2023, 13(7): 3-5.
[8]	刘德城. 降糖宁心汤治疗糖尿病合并心力衰竭的临床疗效观察[J]. 心血管病防治知识, 2023, 13(7): 16-18.
[9]	文武. 多样化护理干预在ICU急性心肌梗死合并糖尿病危重患者中的应用[J]. 心血管病防治知识, 2023, 13(7): 47-49.
[10]	叶小婷, 吴丽钦, 吕淑贞. 利拉鲁肽联合延续性护理对老年慢性心力衰竭伴糖尿病患者心功能及生活质量的影响研究[J]. 心血管病防治知识, 2023, 13(7): 82-84.
[11]	卢丽华. 心肌收缩力储备联合心脏彩超对高龄慢性心力衰竭患者预后的预测效能研究[J]. 心血管病防治知识, 2023, 13(6): 6-8.
[12]	李琼利. 系统化护理干预对连续性血液净化治疗肾衰竭合并重症心力衰竭患者的效果影响[J]. 心血管病防治知识, 2023, 13(6): 36-38.
[13]	许莎琴. 基于微信平台辅助延续性护理结合家庭护理对慢阻肺合并心力衰竭患者依从性的影响[J]. 心血管病防治知识, 2023, 13(6): 52-55.
[14]	周茜. 重组人脑利钠肽联合参附注射液治疗急性心肌梗死合并心力衰竭的效果分析[J]. 心血管病防治知识, 2023, 13(5): 3-5.
[15]	任耒. 一体化急救护理模式对重症肺炎合并心力衰竭患者心肺功能的影响[J]. 心血管病防治知识, 2023, 13(5): 42-45.